Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.